Johnson & Johnson: Time To Buy Before The Split

Dec. 03, 2022 7:30 AM ETJohnson & Johnson (JNJ)140 Comments

Summary

  • JNJ will be spinning off its popular consumer health segment into a separate company called Kenvue.
  • Medical Devices and Pharmaceutical segments will remain together in which they are the fastest growing segments within the business.
  • In a time of much uncertainty surrounding 2023, JNJ is a defensive name with essential products with a rock-solid dividend.
  • Looking for a helping hand in the market? Members of iREIT on Alpha get exclusive ideas and guidance to navigate any climate. Learn More »

Generic brand pain medication vs name brand Tylenol. Pain relief.

CatLane/iStock Unreleased via Getty Images

Johnson & Johnson (NYSE:JNJ) for years has been a safety net for many dividend investors, and that continues to be the case in 2022. In a year in which the S&P 500 (

ycharts.com

ycharts

https://www.cnbc.com/2021/06/01/supreme-court-rejects-johnson-johnsons-appeal-of-2-billion-baby-powder-penalty.html

CNBC

https://seekingalpha.com/symbol/JNJ/dividends/scorecard

Seeking Alpha

Fastgraphs.com

Fast Graphs

No marketing to add

This article was written by

Mark Roussin profile picture
8.62K Followers
Author of iREIT on Alpha
The #1 Service For Safe and Reliable REIT Income

Mark Roussin is an active Certified Public Accountant (CPA) in the state of California. Mark has worked as a CPA, serving both public and private Real Estate corporations for over 10 years. Today, he provides his followers insights to both undervalued dividend stocks mixed with high-growth opportunities with a goal of them reaching financial freedom in the long-term. Mark tends to invest primarily in dividend stocks with a strong emphasis on Real Estate Investment Trusts (REITs). 


Mark has partnered with "iREIT on Alpha”, which is the premiere marketplace service that provides the best daily in-depth REIT research. The service boasts a community of like minded investors that also receive complete access to our various portfolios that you can track in real-time. Come check out all the exclusive content today!

-----------

DISCLAIMER: Mark is not a Registered Investment Advisor or Financial Planner. The Information in his articles and his comments on SeekingAlpha.com or elsewhere is provided for information purposes only. He asks that you perform your own due diligence or seek the advice of a qualified professional. You are responsible for your own investment decisions. 

Disclosure: I/we have a beneficial long position in the shares of JNJ, ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (140)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.